Skip to main content

Methadone Tied to Lower Risk for Discontinuation Versus Buprenorphine/Naloxone

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 18, 2024.

By Lori Solomon HealthDay Reporter

FRIDAY, Oct. 18, 2024 -- Receipt of methadone for opioid use disorder is associated with a lower risk for treatment discontinuation compared with buprenorphine/naloxone, according to a study published online Oct. 17 in the Journal of the American Medical Association.

Bohdan Nosyk, Ph.D., from Simon Fraser University in Burnaby, British Columbia, Canada, and colleagues assessed the risk for treatment discontinuation and mortality among individuals receiving buprenorphine/naloxone versus methadone for the treatment of opioid use disorder. The analysis included 30,891 incident adult users (2010 to 2020) who were not incarcerated, pregnant, or receiving palliative cancer care.

The researchers found that incident users of buprenorphine/naloxone had a higher risk for treatment discontinuation versus methadone in initiator analyses (88.8 versus 81.5 percent discontinued at 24 months; adjusted hazard ratio [HR], 1.58). Similar results were found when evaluated at optimal dose in a per-protocol analysis (42.1 versus 30.7 percent; adjusted HR, 1.67). Mortality while receiving treatment showed ambiguous results in per-protocol analyses (incident users: 0.08 versus 0.13 percent mortality at 24 months; adjusted HR, 0.57; 95 percent confidence interval [CI], 0.24 to 1.35; prevalent users: 0.08 versus 0.09 percent; adjusted HR, 0.97; 95 percent CI, 0.54 to 1.73). Similar results were seen after the introduction of fentanyl and across patient subgroups.

“As the use of more potent synthetic opioids continues to increase in North America and elsewhere, clinical guidelines for all aspects of the treatment of people with opioid use disorders require reconsideration to reduce the risk of discontinuation of treatment,” the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted October 2024

Read this next

Previous Estimates of Illicit Opioid Use in the United States Underreported

WEDNESDAY, May 14, 2025 -- Illicit opioid use may be higher than previously reported in the United States, according to a study published online May 9 in JAMA Health...

Rates of Fentanyl Nonfatal Overdose ED Visits Rose Through Third Quarter of 2023

WEDNESDAY, May 14, 2025 -- From 2020 to 2023, there was an increase in the rates of fentanyl-involved nonfatal overdose emergency department visits, according to research...

Nearly 19 Million Children Live Under Same Roof as Parent With Substance Use Disorder

TUESDAY, May 13, 2025 -- In 2023, nearly 19 million children in the United States were estimated to be living in a household with at least one parent or primary caregiver with a...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.